NASH study

Study name:

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis who Have Type 2 Diabetes or Pre-Diabetes (The CENTRICITY Study)

Eligibility:

Subjects are required to have evidence of Type 2 Diabetes or pre-diabetes (HbA1C of 5.7% to 6.4% at Screening).

Treatment 1:

HTD1801

Treatment 2:

Placebo